CAMM evaluates new approach to evaluating single-drug and pairwise combinations showing promise for predicting the outcome of higher order drug combinations, paving the way for a more efficient approach to prioritizing large numbers of novel TB regimens for further nonclinical and early-phase clinical testing.
